ESMO IOTECH
@esmo_iotech
Followers
354
Following
204
Statuses
163
IOTECH publishes pre-clinical & clinical studies covering natural & therapy-induced innate & adaptive immune responses against solid/haematological cancers
Joined September 2021
IOTECH is the newest @myESMO #OpenAccess journal. We aim to publish the highest quality #immunooncology research and aspire to provide a forum for leaders in the IO field. Led by EIC @HaanenJohn, we look forward to receiving your research manuscripts.
0
9
24
RT @myESMO: The impact of #GutMicrobiota on #immunotherapy response and resistance has been established, but studies presented at #ESMOImmuโฆ
0
4
0
RT @myESMO: #ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, @Schumacher_lab, tackling the T-cell receptor challenge w/ vโฆ
0
3
0
RT @OncologyAdvance: Check out our collection of recently published papers from ESMOโs premier journals, reflecting the themes of the ESMOโฆ
0
2
0
It's finally here! #ESMOImmuno24 ๐ Delighted that all accepted abstracts, including late-breaking abstracts, will be published online in the 'ESMO Immuno-Oncology Congress 2024 Abstract Book', a supplement to @esmo_iotech.
๐ฃ #ESMOImmuno24: J. Haanen, J. Naidoo, K. Harrington and A. di Giacomo highlight the benefits of sharing your research at this event. โฐ Deadline: 1 October ๐
Dates: 11-13 December 2024 ๐ Location: Geneva, Switzerland ๐ Submit your abstract:
0
0
2
RT @myESMO: .@Schumacher_lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 Deceโฆ
0
7
0
RT @myESMO: #ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy.โฏHowever, some challenges still limit its implementationโฆ
0
1
0
Welcome to Geneva ๐จ๐ญ for the much awaited #ESMOImmuno24! ๐ก Presenting your work at #ESMOImmuno24? Looking for a home for your research work? Consider submitting to @esmo_iotech: ๐
0
1
5
๐ข Check out this original article by Konรฏg & colleagues @UniBasel_en @UniSpitalBasel ๐จ๐ญ. ๐ BaseTIL trial: A single-center investigator-initiated phase I study of TILs + nivolumab in patients with advanced melanoma. Available #OpenAccess ๐
0
3
4
๐ข Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet ๐ฉ๐ฐ๐ซ๐ฎ. ๐Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess ๐
0
4
3
RT @OncologyAdvance: Discover what's in store for Immuno-Oncology and Technology! Watch our video to learn about our article types, the subโฆ
0
2
0
๐ข Check out this latest original article by @TGruijl & team @amsterdamumc. ๐งซAn organotypic human melanoma-in-skin model as an in๏ฟฝ๏ฟฝvitro tool for testing Vฮณ9Vฮด2-T cell-based immunotherapy. Available #OpenAccess ๐
0
0
0
๐ข Check out this latest original article by Yeghaian, @S_Trebeschi + colleagues ๐ณ๐ฑ๐จ๐ญ๐ฉ๐ฐ. ๐ฌ Integrated noninvasive dx for prediction of survival in immunotherapy: Longitudinal CT, blood tests & clinical parameters โถ๏ธ AI models. Available #OpenAccess ๐
0
0
0
๐ข Hear first hand from our Editor-in-Chief Prof @HaanenJohn about ESMO IOTECH - @myESMOโs peer-reviewed open-access specialised journal dedicated to publishing advances in immuno-oncology and technology ๐
Discover the latest insights in immuno-oncology and technology! Watch our new video featuring Immuno-Oncology and Technology Editor in Chief John Haanen discussing what authors and readers can expect from the journal. Find out more @esmo_iotech
0
4
8
RT @OncologyAdvance: ๐
Congratulations to Immuno-Oncology and Technology Editor in Chief, John Haanen, for receiving the ESMO Lifetime Achiโฆ
0
6
0
๐ก Presenting your work at #ESMO24 in Barcelona ๐ช๐ธ? Looking for a home for your research work? Consider submitting to @esmo_iotech ๐ ๐
0
4
5
RT @myESMO: #ESMO24: Do not miss the latest #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation. ๐ httโฆ
0
23
0
๐ข Check out this latest original article by van Duin & colleagues - a multicentre study ๐ณ๐ฑ. ๐ฌ Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma. Available #OpenAccess ๐
0
1
1
๐ Latest REVIEW by Olivera & @DrIgMelero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'. Available #OpenAccess ๐
0
2
4
Congratulations to our ESMO IOTECH's Editor-in-Chief @HaanenJohn for the 2024 ESMO Lifetime Achievement Award ๐
. Well-deserved distinction, and we are all so delighted! #ESMO24 @myESMO
#ESMO24: ESMO has announced the recipients of the 2024 ESMO Society Awards in recognition of their work in strengthening the oncology field and supporting fellow oncologists in their professional careers. ๐
0
0
4
๐ There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: @alena_grosvidal & @sklobuch. For further details, please check out:
๐จ SPECIAL ISSUE: Developments in Cell Therapy ๐จ โฐ Submit an original article/review by 1 July 2024 ๐ 2022 CiteScore: 5.5 ๐ Indexed on PMC & PubMed @NLM_NIH: 'Immunooncol Technol' Further details: Guest editors: @alena_grosvidal & @sklobuch
0
3
3